Open AccessClozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
Author(s) -
Silvia Moga,
Andreea Teodorescu,
Petru Ifteni,
Paula-Simina Petric,
Ana-Aliana Miron
Publication year - 2022
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s361405
Subject(s) - medicine , clozapine , neutropenia , covid-19 , schizophrenia (object oriented programming) , virology , psychiatry , intensive care medicine , immunology , infectious disease (medical specialty) , chemotherapy , disease , outbreak
Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed to provide a study on the association between neutropenia and clozapine in patients with schizophrenia and COVID-19.